Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In patients with metastatic breast cancer that is positive for human epidermal growth factor receptor 2 (HER2), progression-free survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and docetaxel, as compared with placebo, trastuzumab, and docetaxel. Overall survival was significantly improved with pertuzumab in an interim analysis without the median being reached. We report final prespecified overall survival results with a median follow-up of 50 months. METHODS: We randomly assigned patients with metastatic breast cancer who had not received previous chemotherapy or anti-HER2 therapy for their metastatic disease to receive the pertuzumab combination or the placebo combination. The secondary end points of overall survival, investigator-assessed progression-free survival, independently assessed duration of response, and safety are reported. Sensitivity analyses were adjusted for patients who crossed over from placebo to pertuzumab after the interim analysis. RESULTS: The median overall survival was 56.5 months (95% confidence interval [CI], 49.3 to not reached) in the group receiving the pertuzumab combination, as compared with 40.8 months (95% CI, 35.8 to 48.3) in the group receiving the placebo combination (hazard ratio favoring the pertuzumab group, 0.68; 95% CI, 0.56 to 0.84; P<0.001), a difference of 15.7 months. This analysis was not adjusted for crossover to the pertuzumab group and is therefore conservative. Results of sensitivity analyses after adjustment for crossover were consistent. Median progression-free survival as assessed by investigators improved by 6.3 months in the pertuzumab group (hazard ratio, 0.68; 95% CI, 0.58 to 0.80). Pertuzumab extended the median duration of response by 7.7 months, as independently assessed. Most adverse events occurred during the administration of docetaxel in the two groups, with long-term cardiac safety maintained. CONCLUSIONS: In patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared with the addition of placebo, significantly improved the median overall survival to 56.5 months and extended the results of previous analyses showing the efficacy of this drug combination. (Funded by F. Hoffmann-La Roche and Genentech; CLEOPATRA ClinicalTrials.gov number, NCT00567190.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the safety and efficacy profiles for SC trastuzumab in combination with IV pertuzumab and docetaxel as a first-line treatment for patients with HER2-positive MBC in the MetaPHER study (NCT02402712) was found to be consistent with those observed for IV trastuzumab in combination with IV pertuzumab and docetaxel in the CLEOPATRA study (NCT00567190) [21, 35–38].”
From A systematic review of time and resource use costs of subcutaneous versus intravenous administration of oncology biologics in a hospital setting (2023) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Self-citationGianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Self-citationSmith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Self-citationvon Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., Maartense, E., Zielinski, C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 676
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Self-citation
Cited by
Items 501–600 of 1,001
Lipid-based nanoparticulate delivery systems for HER2-positive breast cancer immunotherapy
Behravan, N., Zahedipour, F., Jaafari, M. R., Johnston, T. P., & Sahebkar, A. (2022) · Life Sciences · doi:10.1016/j.lfs.2021.120294 · Cited by 35
Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity
Koirala, N., Dey, N., Aske, J. C., & De, P. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126547 · Cited by 36
Cure in metastatic breast cancer
Westphal, T., Gampenrieder, S. P., Rinnerthaler, G., & Greil, R. (2018) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-018-0426-9 · Cited by 37
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial
Goel, S., Pernas, S., Tan‐Wasielewski, Z., Barry, W. T., Bardia, A., Rees, R., Andrews, C., Tahara, R. K., Trippa, L., Mayer, E. L., et al. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.05.010 · Cited by 39
Henry, N. L., Shah, P. D., Haider, I., Freer, P. E., Jagsi, R., & Sabel, M. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00088-8 · Cited by 57
Megid, T. B. C., Farooq, A. R., Wang, X., & Elimova, E. C. (2023) · Cancers · doi:10.3390/cancers15205075 · Cited by 38
HER2-positive metastatic breast cancer: A changing scenario
Mustacchi, G., Biganzoli, L., Pronzato, P., Montemurro, F., Dambrosio, M., Minelli, M., Molteni, L., & Scaltriti, L. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.02.002 · Cited by 34
Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis
Spolverato, G., Vitale, A., Bagante, F., Connolly, R. M., & Pawlik, T. M. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001715 · Cited by 34
Andersson, M., López-Vega, J. M., Petit, T., Zamagni, C., Easton, V., Kamber, J., Restuccia, E., & Perez, E. A. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0079 · Cited by 33
Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk
Dowsett, M., & Turner, N. C. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01412 · Cited by 33
Systemic Therapy of Central Nervous System Metastases of Breast Cancer
Leone, J. P., & Lin, N. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0802-6 · Cited by 33
Spring, L. M., Clark, S. L., Li, T., Goel, S., Tayob, N., Viscosi, E., Abraham, E., Juric, D., Isakoff, S. J., Mayer, E. L., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00311-y · Cited by 36
The value of anticancer drugs — a regulatory view
Pignatti, F., Wilking, U., Postmus, D., Wilking, N. E., Delgado, J., & Bergh, J. C. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00584-z · Cited by 37
Shibata, T., Watari, K., Izumi, H., Kawahara, A., Hattori, S., Fukumitsu, C., Murakami, Y., Takahashi, R., Toh, U., Ito, K., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1593 · Cited by 33
Bertho, M., Fraisse, J., Patsouris, A., Cottu, P. H., Arnedos, M., Pérol, D., Jaffré, A., Gonçalvès, A., Lebitasy, M.-P., D’Hondt, V., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920987657 · Cited by 34
Self-citationMorsberger, L. A., Pallavajjala, A., Long, P., Hardy, M., Park, R., Parish, R., Nozari, A., & Zou, Y. S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02761-1 · Cited by 35
SATO, M., Han, Q., Mori, R., MIZUTA, K., Kang, B. M., Morinaga, S., Kobayashi, N., ICHIKAWA, Y., Nakajima, A., & Hoffman, R. M. (2024) · Anticancer Research · doi:10.21873/anticanres.16946 · Cited by 38
Singh, J. C., Mamtani, A., Barrio, A. V., Morrow, M., Sugarman, S. M., Jones, L. W., Yu, A. F., Argolo, D. F. S. D. T. E., Smyth, L. M., Modi, S., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0268 · Cited by 32
Self-citationOncologists’ and Intensivists’ Attitudes Toward the Care of Critically Ill Patients with Cancer
Nassar, A. P., Dettino, A. L. A., Amêndola, C. P., dos Santos, R. A., Forte, D. N., & Caruso, P. (2017) · Journal of Intensive Care Medicine · doi:10.1177/0885066617716105 · Cited by 32
Lorenzo, C. D., Paciello, R., Riccio, G., Rea, D., Barbieri, A., Coppola, C., & Maurea, N. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s157294 · Cited by 34
Moilanen, T., Jokimäki, A., Tenhunen, O., & Koivunen, J. P. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2682-9 · Cited by 32
Stopeck, A., Brufsky, A., Kennedy, L., Bhatta, S., Bhowmik, D., Buchanan, J., Despiégel, N., & Hechmati, G. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1651122 · Cited by 32
Cobleigh, M., Yardley, D. A., Brufsky, A., Rugo, H. S., Swain, S. M., Kaufman, P. A., Tripathy, D., Hurvitz, S. A., O’Shaughnessy, J., Mason, G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2350 · Cited by 32
Self-citationBouwer, N. I., Steenbruggen, T. G., van Rosmalen, J., Rier, H. N., Kitzen, J. J. E. M., van Bekkum, M. L., ten Tije, A. J., de Jong, P. C., Drooger, J. C., Holterhues, C., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-06039-w · Cited by 32
Kaehler, M., & Cascorbi, I. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.696960 · Cited by 36
Bekaert, L., Emery, É., Levallet, G., & Lechapt, E. (2016) · Brain Tumor Pathology · doi:10.1007/s10014-016-0275-3 · Cited by 35
Robert, N. J., Goertz, H., Chopra, P., Jiao, X., Yoo, B., Patt, D. A., & Antao, V. (2017) · Drugs - Real World Outcomes · doi:10.1007/s40801-016-0102-5 · Cited by 32
Systemic therapy for brain metastases
Venur, V. A., Karivedu, V., & Ahluwalia, M. S. (2018) · Handbook of clinical neurology · doi:10.1016/b978-0-12-811161-1.00011-6 · Cited by 36
Bruniaux, J., Allard-Vannier, É., Aubrey, N., Lakhrif, Z., Djemaa, S. B., Eljack, S., Marchais, H., Hervé-Aubert, K., Chourpa, I., & David, S. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118572 · Cited by 33
Principles of Dose, Schedule, and Combination Therapy
Hait, W. N., & Eder, J. P. (2019) · Wiley eBooks · doi:10.1002/9781119000822.hfcm055.pub2 · Cited by 32
Ismail, A., Desai, A. P., & Boumber, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1624124 · Cited by 36
Awada, G., Gombos, A., Aftimos, P. G., & Awada, A. H. (2016) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2016.1146680 · Cited by 33
Lambertini, M., Ferreira, A. R., Meglio, A. D., Poggio, F. B., Puglisi, F., Sottotetti, F., Montemurro, F., Poletto, E., Bernardo, A., Risi, E., et al. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.04.002 · Cited by 33
Falzone, N., Ackerman, N. L., Rosales, L. D. L. F., Bernal, M. A., Liu, X., Peeters, S. G. J. A., Soto, M. S., Corroyer‐Dulmont, A., Bernaudin, M., Grimoin, E., et al. (2017) · Theranostics · doi:10.7150/thno.22217 · Cited by 31
Redrawing the Lines: The Next Generation of Treatment in Metastatic Breast Cancer
Savard, M.-F., Khan, O. F., Hunt, K. K., & Verma, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237419 · Cited by 31
Liu, T., Qin, Y., Li, J., Xu, R., Xu, J., Yang, S., Qin, S., Bai, Y., Wu, C., Mao, Y., et al. (2019) · 癌症:英文版 · doi:10.1186/s40880-019-0384-6 · Cited by 31
Wardley, A. M., Cortés, J., Provencher, L., Miller, K. D., Chien, A. J., Rugo, H. S., Steinberg, J., Sugg, J. E., Tudor, I. C., Huizing, M. T., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06109-7 · Cited by 33
Self-citationThill, M., Jackisch, C., Janni, W., Müller, V., Albert, U., Bauerfeind, I., Blohmer, J., Budach, W., Dall, P., Diel, I., et al. (2019) · Breast Care · doi:10.1159/000500999 · Cited by 36
Antibody–Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond—A 2023 Review
Xiao, T., Ali, S., Mata, D. G. D. M. M., Lohmann, A. E., & Blanchette, P. (2023) · Current Oncology · doi:10.3390/curroncol30070474 · Cited by 31
González‐de‐Olano, D., Morgado, J. M., Juárez-Guerrero, R., Sánchez‐Muñoz, L., Letéllez-Fernández, J., Malón, D., & Castells, M. (2015) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2015.10.007 · Cited by 31
Gao, C., Zhuang, J., Li, H., Liu, C., Zhou, C., Liu, L., Feng, F., Sun, C., & Wu, J. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01175-1 · Cited by 31
SEOM clinical guidelines in metastatic breast cancer 2015
Gavilá, J., López‐Tarruella, S., Saura, C., Muñoz-Mateu, M., Oliveira, M., de la Cruz‐Merino, L., Morales, S. M., Álvarez, I., Virizuela, J. A., & Martín, M. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1476-7 · Cited by 34
Glück, S. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.08.004 · Cited by 33
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle
Gerratana, L., Bonotto, M., Bozza, C., Ongaro, E., Fanotto, V., Pelizzari, G., & Puglisi, F. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1282944 · Cited by 33
Seidman, A. D., Bordeleau, L. J., Fehrenbacher, L., Barlow, W. E., Perlmutter, J., Rubinstein, L., Wedam, S. B., Hershman, D. L., Hayes, J. F., Butler, L. P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00242 · Cited by 30
Shipunova, V. O., Kotelnikova, P. A., Aghayeva, U. F., Stremovskiy, O. A., Novikov, I. A., Schulga, A. A., Nikitin, M. P., & Deyev, S. M. (2018) · Journal of Magnetism and Magnetic Materials · doi:10.1016/j.jmmm.2018.09.015 · Cited by 30
Residual Disease after Neoadjuvant Therapy — Developing Drugs for High-Risk Early Breast Cancer
Prowell, T. M., Beaver, J. A., & Pazdur, R. (2019) · New England Journal of Medicine · doi:10.1056/nejmp1900079 · Cited by 30
Eligibility of real-world patients with metastatic breast cancer for clinical trials
Batra, A., Kong, S., & Cheung, W. Y. (2020) · The Breast · doi:10.1016/j.breast.2020.10.005 · Cited by 31
Direct targeting of amplified gene loci for proapoptotic anticancer therapy
Tiwari, M. K., Colón-Ríos, D. A., Tumu, H. C. R., Liu, Y., Quijano, E., Krysztofiak, A., Chan, C., Song, E., Braddock, D. T., Suh, H., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01057-5 · Cited by 30
Uijen, M. J. M., Lassche, G., Grunsven, A. C. H. V. E., Driessen, C. M. L., & van Herpen, C. M. L. (2022) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105703 · Cited by 30
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside
Meattini, I., Livi, L., Lorito, N., Becherini, C., Bacci, M., Visani, L., Fozza, A., Belgioia, L., Loi, M., Mangoni, M., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102417 · Cited by 31
Bedard, P. L., Li, S., Wisinski, K. B., Yang, E. S.-H., Limaye, S. A., Mitchell, E. P., Zwiebel, J. A., Moscow, J. A., Gray, R. J., Wang, V., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00165 · Cited by 30
Kourié, H. R., Chaix, M., Gombos, A., Aftimos, P., & Awada, A. H. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1198317 · Cited by 34
Canonici, A., Ivers, L. P., Conlon, N. T., Pedersen, K., Gaynor, N., Browne, B. C., O’Brien, N. A., Gullo, G., Collins, D. M., O’Donovan, N., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0649-y · Cited by 35
Circular RNAs: biology and clinical significance of breast cancer
Wang, Z., Deng, H., Yao, J., Luo, M., Huang, J., Wang, J., Zhang, K., Wang, L., & Zhou, J. (2023) · RNA Biology · doi:10.1080/15476286.2023.2272468 · Cited by 29
Otsuka, M., Yamasaki, O., Kaji, T., Shien, T., & Iwatsuki, K. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.2507 · Cited by 29
Targeting dormant micrometastases: rationale, evidence to date and clinical implications
Hurst, R. E., Bastian, A., Bailey‐Downs, L. C., & Ihnat, M. A. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015624277 · Cited by 32
Charlebois, R., Allard, B., Allard, D., Buisseret, L., Turcotte, M., Pommey, S., Chrobák, P., & Stagg, J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1873 · Cited by 30
Zhong, P., Gu, X., Cheng, R., Deng, C., Meng, F., & Zhong, Z. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146505 · Cited by 31
Fabi, A., Giannarelli, D., Moscetti, L. I., Santini, D., Zambelli, A., Laurentiis, M. D., Caruso, M., Generali, D., Valle, E., Leonardi, V. B., et al. (2017) · Future Oncology · doi:10.2217/fon-2017-0336 · Cited by 29
Nikkhoi, S. K., Rahbarizadeh, F., Ahmadvand, D., & Moghimi, S. M. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.06.019 · Cited by 31
Li, X., Xia, S., Zhou, W., Ji, R., & Zhan, W. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s189252 · Cited by 29
In vitro cytotoxicity of Auger electron-emitting [67Ga]Ga-trastuzumab
Othman, M. F., Verger, E., Costa, I. M., Tanapirakgul, M., Cooper, M. S., Imberti, C., Lewington, V. J., Blower, P. J., & Terry, S. Y. A. (2019) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2019.12.004 · Cited by 29
Zhang, Y., Lun, X., & Guo, W. (2020) · Oncology Letters · doi:10.3892/ol.2020.12255 · Cited by 29
Xu, L., Zhou, Z. Y., Gou, X., Shi, W., Gong, Y., Yi, M., Cheng, W., & Song, F. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113064 · Cited by 29
Xie, S., Wang, Y., Gong, Z., Li, Y., Yang, W., Li, J., Li, J., Hu, X., Wang, Y., Tong, Y., et al. (2022) · Journal of Cancer · doi:10.7150/jca.66567 · Cited by 33
Integrating antibody drug conjugates in the management of gynecologic cancers
Chelariu-Raicu, A., Mahner, S., Moore, K. N., Lorusso, D., & Coleman, R. L. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-003701 · Cited by 31
Antonarelli, G., Corti, C., Tarantino, P., Salimbeni, B. T., Zagami, P., Marra, A., Trapani, D., Tolaney, S. M., Cortés, J., & Curigliano, G. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101608 · Cited by 30
Self-citationMusolino, A., Naldi, N., Dieci, M. V., Zanoni, D., Rimanti, A., Boggiani, D., Sgargi, P., Generali, D., Piacentini, F., Ambroggi, M., et al. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.51 · Cited by 30
Neratinib for the treatment of HER2-positive early stage breast cancer
Echavarría, I., López‐Tarruella, S., Márquez‐Rodas, I., Jerez, Y., & Martín, M. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1338954 · Cited by 29
Decker, T. W., Overkamp, F., Rösel, S., Nusch, A., Göhler, T., Indorf, M., Sahlmann, J., & Trarbach, T. (2017) · BMC Cancer · doi:10.1186/s12885-017-3492-1 · Cited by 29
Omarini, C., Bettelli, S. R., Caprera, C., Manfredini, S., Caggia, F., Guaitoli, G., Moscetti, L. I., Toss, A., Cortesi, L., Kaleci, S., et al. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1480287 · Cited by 29
Optimal Management of Early and Advanced HER2 Breast Cancer
Hurvitz, S. A., Gelmon, K. A., & Tolaney, S. M. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175630 · Cited by 29
Elebro, J., Heby, M., Warfvinge, C. F., Nodin, B., Eberhard, J., & Jirström, K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153533 · Cited by 28
Escalating and de-escalating treatment in HER2-positive early breast cancer
Joensuu, H. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.002 · Cited by 31
Park, J. C., Ma, T. M., Rooper, L. M., Hembrough, T., Foss, R. D., Schmitt, N. C., Sawhney, R., Flanders, A. W., & Kang, H. (2018) · Head & Neck · doi:10.1002/hed.25392 · Cited by 28
A multistate model for early decision‐making in oncology
Beyer, U., Dejardin, D., Meller, M., Rufibach, K., & Burger, H. U. (2019) · Biometrical Journal · doi:10.1002/bimj.201800250 · Cited by 32
Prognostic and therapeutic molecular markers in the clinical management of esophageal cancer
Zhou, N., & Hofstetter, W. L. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1731307 · Cited by 29
Management of Brain and Leptomeningeal Metastases from Breast Cancer
Pellerino, A., Internò, V., Mo, F., Franchino, F., Soffietti, R., & Rudà, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228534 · Cited by 31
Flexible care in breast cancer
Wardley, A. M., Canon, J. L., Elsten, L., Murillo, C. P., Črnjević, T. B., Fredriksson, J., & Piccart, M. J. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100007 · Cited by 31
The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status
Zhao, H., & Gong, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.643956 · Cited by 28
Therapeutic landscape of advanced HER2-positive breast cancer in 2022
Gupta, R., Gupta, S., Antonios, B., Ghimire, B., Jindal, V., Deol, J., Gaikazian, S., Huben, M. T., Anderson, J., Stender, M., et al. (2022) · Medical Oncology · doi:10.1007/s12032-022-01849-y · Cited by 35
Xu, B., Li, W., Zhang, Q., Li, Q., Wang, X., Li, H., Sun, T., Yin, Y., Zheng, H. Y., Feng, J., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06775-1 · Cited by 30
Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives
Liu, L., & Chen, J. (2022) · Medical Review · doi:10.1515/mr-2022-0033 · Cited by 29
Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
Subhan, M. A., & Torchilin, V. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041242 · Cited by 30
van Reesema, L. L. S., Zheleva, V. P., Winston, J. S., Jansen, R. J., O’Connor, C. F., Isbell, A. J., Bian, M., Qin, R., Bassett, P. T., Hinson, V. J., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.014 · Cited by 28
Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis
Niikura, N., Shimomura, A., Fukatsu, Y., Sawaki, M., Ogiya, R., Yasojima, H., Fujisawa, T., YAMAMOTO, M., Tsuneizumi, M., Kitani, A., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4489-9 · Cited by 28
Singh, H., Kang, A., Bloudek, L. M., Hsu, L., Palanca-Wessels, M. C., Stecher, M., Siadak, M. F., & Ng, K. (2023) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkad082 · Cited by 28
Iwata, H., Xu, B., Kim, S., Chung, W., Park, Y. H., Kim, M. H., Tseng, L., Chung, C.-F., Huang, C., Kim, J. H., et al. (2024) · Cancer Science · doi:10.1111/cas.16234 · Cited by 27
Self-citationCaccese, M., Ferrara, R., Pilotto, S., Carbognin, L., Grizzi, G., Caliò, A., Brunelli, M., Cuppone, F., Petraglia, S., Scarpa, A., et al. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1242578 · Cited by 27
Honkanen, T. J., Moilanen, T., Karihtala, P., Tiainen, S., Auvinen, P., Väyrynen, J. P., Mäkinen, M. J., & Koivunen, J. P. (2017) · Scientific Reports · doi:10.1038/s41598-017-18266-1 · Cited by 27
Kjær, I. M., Bechmann, T., Brandslund, I., & Madsen, J. S. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2017-0592 · Cited by 28
Minasian, L. M., Dimond, E. P., Davis, M., Adhikari, B. B., Fagerstrom, R. M., Fabian, C. J., Floyd, J. D., Unger, J. M., Douglas, P. S., Mustian, K. M., et al. (2019) · JACC CardioOncology · doi:10.1016/j.jaccao.2019.08.007 · Cited by 29
The Evolving Landscape of HER2-Directed Breast Cancer Therapy
Marti, J. L. G., Hyder, T., Nasrazadani, A., & Brufsky, A. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00780-6 · Cited by 29
Sultova, E., Westphalen, C. B., Jung, A., Kumbrink, J., Kirchner, T., Mayr, D. C., Rudelius, M., Ormanns, S., Heinemann, V., Metzeler, K. H., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11040733 · Cited by 30
Clinical Trials of Oncolytic Viruses in Breast Cancer
Carter, M. E., Koch, A., Lauer, U. M., & Hartkopf, A. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.803050 · Cited by 29
Liu, X., Fang, Y., Li, Y., Li, Y., Qi, L., & Wang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894861 · Cited by 30
Lei, H., Ling, Y., Yuan, P., Yan, X., Wang, L., Shi, Y., Yao, X., Luo, H., Shi, B., Liu, J., et al. (2023) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2023.02.003 · Cited by 27
Arimori, T., Mihara, E., Suzuki, H., Ohishi, T., Tanaka, T., Kaneko, M. K., Takagi, J., & Kato, Y. (2024) · Structure · doi:10.1016/j.str.2024.02.007 · Cited by 29
Jehn, C. F., Hemmati, P., Lehenbauer-Dehm, S., Kümmel, S., Flath, B. C., & Schmid, P. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.06.001 · Cited by 28
Metadata
- Authors
- Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., Clark, E., Ross, G., Benyunes, M. C., & Cortés, J.
- Affiliations
- MedStar Washington Hospital Center (US)
- Asan Medical Center (KR)
- National Cancer Center (KR)
- Institute of Oncology NN Petrov (RU)
- Hospital Universitario 12 De Octubre (ES)
- Centre Antoine Lacassagne (FR)
- University Hospital Heidelberg (DE)
- Roche (United Kingdom) (GB)
- Genentech (US)
- Vall d'Hebron Hospital Universitari (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-02-19
- Volume
- 372
- Issue
- 8
- Pages
- 724-734
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5584549
- OpenAlex
- W2137228442
- Cited by
- 2,164
- References
- 26
- Citations by year
- 2026: 138 · 2025: 150 · 2024: 157 · 2023: 197 · 2022: 191 · 2021: 212 · 2020: 206 · 2019: 217 · 2018: 202 · 2017: 207 · 2016: 197 · 2015: 87
- FWCI
- 100.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Tampere University Institutional Repository (Tampere University) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- Genentech
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- pertuzumab, trastuzumab, docetaxel, HER2-positive breast cancer, metastatic breast cancer, overall survival, progression-free survival, duration of response, cardiac safety, HER2-targeted therapy, first-line chemotherapy
- MeSH terms
- Trastuzumab, Docetaxel, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Infusions, Intravenous, Middle Aged, Neoplasm Metastasis, Survival Analysis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Taxoids, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.